ConductScience.org, home

Paper41323732

Unravelling targeted therapy in prostate cancer: from molecular mechanisms to translational opportunities.

Wu L and 5 others. Front Cell Dev Biol, 2025. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Unravelling targeted therapy in prostate cancer: from molecular mechanisms to translational opportunities. Papers, record 41323732. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41323732

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Unravelling targeted therapy in prostate cancer: from molecular mechanisms to translational opportunities.
PubMed
Journal
Front Cell Dev Biol
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
2
iCite
Revised in PubMed
2025-12-03
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wu LLitong
2Qiu JJunfeng
3Hong ZZhiming
4Wang QQuan
5Li QQixin
6Zhou WWenbin

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References128

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133339441Various Aspects of a Gene Editing System-CRISPR-Cas9.Int J Mol Sci2020https://conductscience.org/library/papers/33339441PubMed
236229464Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease.Nat Commun2022https://conductscience.org/library/papers/36229464PubMed
337832401Exploring the role of PI3K/AKT/mTOR inhibitors in hormone-related cancers: A focus on breast and prostate cancer.Biomed Pharmacother2023https://conductscience.org/library/papers/37832401PubMed
425139413PTEN loss-mediated Akt activation increases the properties of cancer stem-like cell populations in prostate cancer.Oncology2014https://conductscience.org/library/papers/25139413PubMed
534572980Comparative Cytotoxic Activity of Hydroxytyrosol and Its Semisynthetic Lipophilic Derivatives in Prostate Cancer Cells.Antioxidants (Basel)2021https://conductscience.org/library/papers/34572980PubMed
627197252Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity.Cancer Res2016https://conductscience.org/library/papers/27197252PubMed
732778095
Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
BMC Cancer2020https://conductscience.org/library/papers/32778095PubMed
835468964HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer.Nat Genet2022https://conductscience.org/library/papers/35468964PubMed
936919762Metabolic shift towards oxidative phosphorylation reduces cell-density-induced cancer-stem-cell-like characteristics in prostate cancer in vitro.Biol Open2023https://conductscience.org/library/papers/36919762PubMed
1033754187Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE).Cancer Chemother Pharmacol2021https://conductscience.org/library/papers/33754187PubMed
1136519314Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment.Expert Opin Ther Targets2022https://conductscience.org/library/papers/36519314PubMed
1237922438Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591.J Clin Oncol2024https://conductscience.org/library/papers/37922438PubMed
1340705094Efficacy and safety of rechallenge therapy with [177Lu]Lu-PSMA in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.Eur J Nucl Med Mol Imaging2025https://conductscience.org/library/papers/40705094PubMed
1433557050Treating Prostate Cancer by Antibody-Drug Conjugates.Int J Mol Sci2021https://conductscience.org/library/papers/33557050PubMed
1537797680Survivin-targeted nanomedicine for increased potency of abiraterone and enzalutamide against prostate cancer.Eur J Pharm Biopharm2023https://conductscience.org/library/papers/37797680PubMed
1633781305Prostate cancer and PARP inhibitors: progress and challenges.J Hematol Oncol2021https://conductscience.org/library/papers/33781305PubMed
1737298192Flavones: The Apoptosis in Prostate Cancer of Three Flavones Selected as Therapeutic Candidate Models.Int J Mol Sci2023https://conductscience.org/library/papers/37298192PubMed
1835532818The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors.Cell Mol Life Sci2022https://conductscience.org/library/papers/35532818PubMed
1934919143Lipid-loaded tumor-associated macrophages sustain tumor growth and invasiveness in prostate cancer.J Exp Med2022https://conductscience.org/library/papers/34919143PubMed
2033643546Covalent conjugation of extracellular vesicles with peptides and nanobodies for targeted therapeutic delivery.J Extracell Vesicles2021https://conductscience.org/library/papers/33643546PubMed

See all 128 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
42882486Homoharringtonine Suppresses Prostate Cancer Progression Through Modulation of the TNF/NF-κB and MAPK Signaling Pathways.Cells2026https://conductscience.org/library/papers/42882486PubMed
42511541Serum CCL2 and CCL7 in Prostate Cancer: Evaluation of Their Diagnostic Utility in Comparison with Benign Prostatic Hyperplasia and Healthy Controls.Int J Mol Sci2026https://conductscience.org/library/papers/42511541PubMed
42122189CRLF1 Drives Prostate Cancer Progression via COMP-Mediated Activation of the FAK/PI3K/AKT Signaling Pathway.Cancers (Basel)2026https://conductscience.org/library/papers/42122189PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
MTOR2475PubTator's text mininghttps://conductscience.org/library/genes/2475NCBI Gene
PIK3CB5291PubTator's text mininghttps://conductscience.org/library/genes/5291NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41323732

GET https://conductscience.org/api/papers/v1/41323732/references?page=2